# Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

> **NCT05699655** · PHASE2,PHASE3 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 130 (estimated)

## Conditions studied

- Immunotherapy Gastrict Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** apatinib
- **DRUG:** oxaliplatin
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT05699655
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-10
- **Primary completion:** 2025-03-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699655, "Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05699655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*